Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, et al. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:716–26.

Article  CAS  PubMed  Google Scholar 

Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33:3356–64.

Article  PubMed  Google Scholar 

Larkins E, Blumenthal GM, Yuan W, He K, Sridhara R, Subramaniam S, et al. FDA approval Summary: Pembrolizumab for the treatment of recurrent or metastatic Head and Neck squamous cell carcinoma with Disease Progression on or after platinum-containing chemotherapy. Oncologist. 2017;22:873–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–46.

Article  CAS  PubMed  Google Scholar 

Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of Pembrolizumab with Tumor Response and Survival among patients with Advanced Melanoma. JAMA. 2016;315:1600–9.

Article  CAS  PubMed  Google Scholar 

Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–17.

Article  CAS  PubMed  Google Scholar 

Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018;19:1338–50.

Article  CAS  PubMed  Google Scholar 

Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, et al. Efficacy, Safety, and correlative biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39:704–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma B, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, et al. Antitumor Activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018;36:1412–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ai QY, King AD, Chan J, Chen W, Chan KCA, Woo JKS, et al. Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. Eur Radiol. 2019;29:5627–34.

Article  PubMed  Google Scholar 

Chen Y, Liu X, Zheng D, Xu L, Hong L, Xu Y, et al. Diffusion-weighted magnetic resonance imaging for early response assessment of chemoradiotherapy in patients with nasopharyngeal carcinoma. Magn Reson Imaging. 2014;32:630–7.

Article  CAS  PubMed  Google Scholar 

Liu LT, Guo SS, Li H, Lin C, Sun R, Chen QY, et al. Percent change in apparent diffusion coefficient and plasma EBV DNA after induction chemotherapy identifies distinct prognostic response phenotypes in advanced nasopharyngeal carcinoma. BMC Cancer. 2021;21:1320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meng N, Wang X, Sun J, Han D, Bai Y, Wei W, et al. A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer. Eur Radiol. 2021;31:1707–17.

Article  CAS  PubMed  Google Scholar 

Li L, Chen W, Yan Z, Feng J, Hu S, Liu B, et al. Comparative analysis of Amide Proton transfer MRI and diffusion-weighted imaging in assessing p53 and Ki-67 expression of rectal adenocarcinoma. J Magn Reson Imaging. 2020;52:1487–96.

Article  PubMed  Google Scholar 

Meng N, Fu F, Feng P, Li Z, Gao H, Wu Y, et al. Evaluation of Amide Proton transfer-weighted imaging for Lung Cancer subtype and epidermal growth factor receptor: a comparative study with diffusion and metabolic parameters. J Magn Reson Imaging. 2022;56:1118–29.

Article  PubMed  Google Scholar 

Meyer HJ, Hohn AK, Surov A. Relationships between apparent diffusion coefficient (ADC) histogram analysis parameters and PD-L 1-expression in head and neck squamous cell carcinomas: a preliminary study. Radiol oncol. 2021;55:150–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yilmaz TF, Yurtsever I, Turk HM, Gultekin MA, Besiroglu M, Cesme DH, et al. Relationship with programmed cell death ligand 1 (PD-L1) and DTI features in Brain Metastases of Non-small Cell Lung Cancer: a preliminary study. Curr Med Imaging. 2021;17:1369–73.

Article  PubMed  Google Scholar 

Saada-Bouzid E, Peyrade F, Guigay J. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. Curr Opin Oncol. 2019;31:146–51.

Article  PubMed  Google Scholar 

Zhong X, Tang H, Guan T, Lu B, Zhang C, Tang D, et al. Added value of quantitative apparent diffusion coefficients for identifying small Hepatocellular Carcinoma from Benign Nodule categorized as LI-RADS 3 and 4 in cirrhosis. J Clin Transl Hepatol. 2022;10:34–41.

Article  PubMed  Google Scholar 

Ye XH, Gao JY, Yang ZH, Liu Y. Apparent diffusion coefficient reproducibility of the pancreas measured at different MR scanners using diffusion-weighted imaging. J Magn Reson Imaging. 2014;40:1375–81.

Article  PubMed  Google Scholar 

Kim SY, Lee SS, Byun JH, Park SH, Kim JK, Park B, et al. Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology. 2010;255:815–23.

Article  PubMed  Google Scholar 

Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71:25–38.

Article  CAS  PubMed  Google Scholar 

Meng N, Fu F, Sun J, Tang W, Zhang L, Xie S, et al. Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and (18)F-FDG PET. Quant Imaging Med Surg. 2022;12:4474–87.

Article  PubMed  PubMed Central  Google Scholar 

Zhao L, Zhuang Y, Fu K, Chen P, Wang Y, Zhuo J, et al. Usefulness of [(18)F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2020;47:1065–74.

Article  CAS  PubMed  Google Scholar